US Patent 7872014 Anaplastic lymphoma kinase modulators and methods of use
Patent 7872014 was granted and assigned to Exelixis on January, 2011 by the United States Patent and Trademark Office.
All edits
Edits on 27 Nov, 2023
Golden AI
Edits made to:
Article (+372 characters)
Article
Patent abstract
The present invention comprises compounds and pharmaceutical compositions comprising the compounds that are inhibitors of ALK. The invention also comprises methods of using the compounds and compositions to treat diseases mediated by ALK, including diseases such as cancer, immunological disorders, cardiovascular diseases, and other degenerative disorders.
Edits on 19 Sep, 2023
Golden AI
Edits made to:
Infobox (+14 properties)
Infobox
Patent Inventor Names
Abigail R. Kennedy0
Angie I. Kim0
Charles M. Blazey0
Csaba J. Peto0
Jean-Claire L. Manalo0
Jeffry Kimo Curtis0
Joerg Bussenius0
Kenneth D. Rice0
Larisa Dubenko0
Neel Kumar Anand0
Owen Joseph Bowles0
Richard G. Khoury0
Simona Costanzo0
Tsze H. Tsang0
Edits on 24 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07872014 Anaplastic lymphoma kinase modulators and methods of use US Patent 7872014 Anaplastic lymphoma kinase modulators and methods of use
Infobox
Patent Number
07872014
Patent Number
7872014
Edits on 4 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 6 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07872014 Anaplastic lymphoma kinase modulators and methods of use
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07872014
Date of patent
January 18, 2011
Patent application number
10565657
Date Filed
July 23, 2004
Patent primary examiner
Find more entities like US Patent 7872014 Anaplastic lymphoma kinase modulators and methods of use
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.